Mangalam Drugs And Organics Peer Comparison

Mangalam Drugs And Organics Ltd. is underperforming relative to its peers in the pharmaceuticals sector, exhibiting negative returns on equity and asset metrics, low revenue growth, and a high PEG ratio indicating overvaluation compared to growth. This positions it as a sector laggard with significant room for improvement in profitability and financial health.

• • Mangalam Drugs shows negative ROE and ROA, indicating poor profitability.
• • High PEG ratio reveals overvaluation despite stagnant revenue and earnings growth.
• • Compared to peers, the company has the highest debt-equity ratio among low-performers.

• • Cipla Ltd.: Highest profitability with strong growth metrics and low valuation ratios.
• • Dr. Reddy's Laboratories Ltd.: Excellent ROE and ROA, combined with attractive valuation metrics and solid revenue growth.
• • Mankind Pharma Ltd.: Strong growth trajectory with healthy profitability and reasonable valuation.